Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | Chief Commercial Officer | July 01, 2022 | July 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date July 01, 2022 · Filed July 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,450 |
Reported balance
After 2022-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-07-01 · Grant · Acquired 35,950 · Balance 46,450 F1: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023. F2: Includes unvested Restricted Stock Units. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2032-07-01 | Direct | 20,650 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Grant · Acquired 20,650 · Balance 20,650 F3: These Stock Options vest in four equal annual installments beginning on August 20, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023.
F2: Includes unvested Restricted Stock Units.
F3: These Stock Options vest in four equal annual installments beginning on August 20, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 6, 2022 18:56 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 20,650 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001209191-22-041377 · doc4.xml · derivative · entry 2 Liberto Erin · CIK 0001816245 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,650 Underlying: Common Stock · 20,650 shares Expires 2032-07-01 F3 · derivative.exercise_date: These Stock Options vest in four equal annual installments beginning on August 20, 2023. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 18:56 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 35,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-041377 · doc4.xml · nonDerivative · entry 1 Liberto Erin · CIK 0001816245 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,450 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023. F2 · balance_after: Includes unvested Restricted Stock Units. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 16:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 6,925 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001209191-21-054953 · doc4.xml · derivative · entry 3 Liberto Erin · CIK 0001816245 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,925 Underlying: Common Stock · 6,925 shares Expires 2031-07-06 F3 · derivative.exercise_date: These Stock Options vest in four equal annual installments upon the satisfaction of certain performance-based vesting criteria with respect to the particular portion of such Stock Options. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 16:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-054953 · doc4.xml · nonDerivative · entry 1 Liberto Erin · CIK 0001816245 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments upon the satisfaction of certain performance-vesting criteria with respect to the particular portion of Restricted Stock Units. Read SEC document |
| May 18, 2021 Filed Sep 7, 2021 16:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-21-054953 · doc4.xml · derivative · entry 2 Liberto Erin · CIK 0001816245 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 6,000 shares Expires 2027-09-06 F2 · derivative.exercise_date: These Stock Options were originally granted on September 6, 2017 and vested on May 18, 2021, upon the satisfaction of a performance-based vesting condition. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:02 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-20-050220 · doc4.xml · derivative · entry 1 Liberto Erin · CIK 0001816245 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 6,000 shares Expires 2027-09-06 F1 · security: These Stock Options were originally exercisable for ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020 (the "Scheme"), the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable. F2 · derivative.exercise_price: The exercise price was converted from A$6.3, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (September 6, 2017). The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise. F3 · date: On September 9, 2020, the performance-based vesting condition with respect to these 6,000 Stock Options was satisfied. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.